Trials / Recruiting
RecruitingNCT06943586
Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing in Patients With Minor Stroke or High Risk TIA (CYP2C19 and Stroke)
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- Sponsor
- University of Alabama at Birmingham · Academic / Other
- Sex
- All
- Age
- 18 Years – 89 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic attack (TIA) patients during their hospital stay.
Detailed description
This is a pilot clinical trial for feasibility
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | CYP2C19 Genotype Guided DAPT (dual antiplatelet therapy) | CYP2C19 is a gene that encodes an enzyme responsible for metabolizing several medications, including the antiplatelet drugs. |
Timeline
- Start date
- 2025-04-09
- Primary completion
- 2028-04-01
- Completion
- 2029-04-01
- First posted
- 2025-04-24
- Last updated
- 2025-04-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06943586. Inclusion in this directory is not an endorsement.